AU2024314540A1 - Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect - Google Patents

Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect

Info

Publication number
AU2024314540A1
AU2024314540A1 AU2024314540A AU2024314540A AU2024314540A1 AU 2024314540 A1 AU2024314540 A1 AU 2024314540A1 AU 2024314540 A AU2024314540 A AU 2024314540A AU 2024314540 A AU2024314540 A AU 2024314540A AU 2024314540 A1 AU2024314540 A1 AU 2024314540A1
Authority
AU
Australia
Prior art keywords
crystal
compound
powder
diffraction
diffraction angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024314540A
Other languages
English (en)
Inventor
Tomoya Iwata
Masato Kono
Noriyuki Takata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2024314540A1 publication Critical patent/AU2024314540A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2024314540A 2023-06-19 2024-06-18 Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect Pending AU2024314540A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023100075 2023-06-19
JP2023-100075 2023-06-19
PCT/JP2024/022040 WO2024262491A1 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Publications (1)

Publication Number Publication Date
AU2024314540A1 true AU2024314540A1 (en) 2025-11-27

Family

ID=93935419

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024314540A Pending AU2024314540A1 (en) 2023-06-19 2024-06-18 Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect

Country Status (9)

Country Link
EP (1) EP4696692A1 (cg-RX-API-DMAC7.html)
JP (1) JP7904995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20260023529A (cg-RX-API-DMAC7.html)
CN (1) CN121152792A (cg-RX-API-DMAC7.html)
AU (1) AU2024314540A1 (cg-RX-API-DMAC7.html)
IL (1) IL324833A (cg-RX-API-DMAC7.html)
MX (1) MX2025014082A (cg-RX-API-DMAC7.html)
TW (1) TW202504613A (cg-RX-API-DMAC7.html)
WO (1) WO2024262491A1 (cg-RX-API-DMAC7.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
US20190380992A1 (en) 2014-12-04 2019-12-19 Biogen Ma Inc. Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
GB202005852D0 (en) 2020-04-22 2020-06-03 C4X Discovery Ltd Therapeutic compounds
CN114507181B (zh) 2020-11-17 2024-03-26 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
CR20240325A (es) 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2

Also Published As

Publication number Publication date
TW202504613A (zh) 2025-02-01
JP7904995B2 (ja) 2026-08-13
IL324833A (en) 2026-01-01
MX2025014082A (es) 2026-01-07
KR20260023529A (ko) 2026-02-20
EP4696692A1 (en) 2026-02-18
JPWO2024262491A1 (cg-RX-API-DMAC7.html) 2024-12-26
CN121152792A (zh) 2025-12-16
WO2024262491A1 (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
CN103694236B (zh) 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物
CN109776445B (zh) 苯并噁二唑类化合物及其制备方法和医药用途
CN110582491B (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2023011513A1 (zh) Shp2抑制剂、包含其的药物组合物及其用途
CN114685488A (zh) 作为sos1抑制剂的化合物及其应用
JP7017801B2 (ja) Creb結合タンパク質(cbp)の阻害
WO2015127872A1 (zh) 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN115867556A (zh) Lpa受体拮抗剂及其用途
JP7286299B2 (ja) 1-メチル-d-トリプトファンの塩及びプロドラッグ
EP3789383B9 (en) Inhibitors of the trpc3 or trpc6 channel
JP7835446B2 (ja) 新規な複素環式化合物
EP3209652B1 (en) Tricyclic atropisomer compounds
CN110198938A (zh) 作为蛋白质聚集调节剂的双-杂芳基衍生物
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
CN108727295A (zh) 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途
CN111377873A (zh) 氨基嘧啶化合物及其制备方法和用途
CN102757448B (zh) 大环类激酶抑制剂化合物、制备方法及其作为药物的应用
CN113272315B (zh) 一类类固醇化合物及其用途
CA3291766A1 (en) Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
IL324833A (en) Crystal of a nitrogen-containing heterocyclic compound with an Nrf2 activating effect
WO2019166616A1 (en) Pyrazole derivatives as nhibitors of the wnt signalling pathway
CN116640122A (zh) Ikzf2降解剂及包含其的药物组合物和用途
WO2019141096A1 (zh) 取代脲类化合物及其制备方法和用途
WO2026042088A1 (en) Trycyclic derivatives and their use as complement factor b inhibitors
WO2026092276A1 (zh) 用于抑制ptpn蛋白的化合物及其用途